Although not as effective as oral acetazolamide, topical dorzolamide was reported to provide significant intraocular pressure reduction in one group of 11 pediatric glaucoma patients (35.7% and 27 ...

Patients should be treated with anti-inflammatories for 7 to 14 days postprocedure, specifically a corticosteroid 4 times per day such as Pred Forte (Allergan Inc., Irvine, CA), prednisolone ...

BRATISLAVA - Počas letných dní sme všetci radi za slnečné a teplé počasie. Keď sa ale objavia extrémne horúčavy, môže nám to priniesť nemilé zdravotné komplikácie. Júnové počasie pripomína v dnešných ...

In 2023, the U.S. uveitis treatment market was valued at USD 0.71 billion and is forecast to grow to USD 1.44 billion by 2032, reflecting a CAGR of 8.09% during the forecast period. The U.S ...

SNS Insider Reveals Strategic Outlook for the U.S. Uveitis Treatment Market—Valued at USD 0.71 Billion in 2023—With the Nation Poised to Maintain North American Dominance Amid Rising Adoption of ...

September 24 to 25, 2025 Digital Transformation Week Expo Europe Amsterdam, NL September 24 to 25, 2025 AI & Big Data Expo Europe 2025 Amsterdam, NL September 29 to 30, 2025 GAI World 2025 Boston, MA ...

Aim is an open-source, self-hosted ML experiment tracking tool designed to handle 10,000s of training runs. Aim provides a performant and beautiful UI for exploring and comparing training runs.

BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has received U.S. Food and Drug Administration approval for prednisolone acetate ophthalmic suspension, 1% sterile, the company announced ...

Amneal plans to launch the product in the third quarter of 2025. According to IQVIA, U.S. annual sales for prednisolone acetate ophthalmic suspension for the 12 months ended April 2025 were about ...

BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of ...

Key complex product approval in the Affordable Medicines segment this year Commercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal ...